| Purpose | Announcement Date | Split Date | Record Date | Face Value (before split) | Face Value (after split) |
|---|---|---|---|---|---|
| Split | 27 Jul 2024 | 28 Oct 2024 | 28 Oct 2024 | 5 | 1 |
| Outcome of Board Meeting Fixation of Record date for Sub-division / split of the Equity shares of the Company pursuant to Regulation 42 of the SEBI (LODR) Regulations, 2015 (As Per BSE Announcement dated on 04.10.2024) Trading Members of the Exchange are hereby informed that DR.REDDYS LABORATORIES LTD., has fixed Record Date for the purpose of Sub-Division of Equity Shares of the Company :- DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE DR.REDDYS LABORATORIES LTD. (500124) RECORD DATE 28/10/2024 PURPOSE Subdivision of existing Equity Shares from One Equity Share of Rs.5/- each into Five Equity Shares of Re.1/- each. SUB-DIVIDED PAID-UP VALUE Re.1/- SUB-DIVIDED PAID-UP VALUE W.E.F. 28/10/2024 DR-745/2024-2025 Note: - i. ISIN No. INE089A01023 of Rs.5/- paid up will not be valid for transactions done on the Exchange on or after 28/10/2024. ii. The new ISIN Number for Re. 1/- paid up will be informed to the market by a separate notice. (As Per BSE Notice Dated on 14.10.2024) Sub: Change in ISIN - Dr. Reddys Laboratories Limited (DRREDDY) Members of the Exchange are hereby informed that the ISIN Code for the equity shares of the following company shall be changed w.e.f. October 28, 2024. New ISIN INE089A01031 Remarks Sub-Division from Rs. 5/- to Re. 1/- The new ISIN shall be effective for all trades done on and from the Ex-date date i.e., October 28, 2024. For and on behalf of National Stock Exchange of India Limited (As Per NSE Circular Dated on 22.10.2024) | |||||
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.
Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore.
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.
Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.
Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.
Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.
EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
